Syneos Health exec jumps ship to Canadian CRO Altasciences

Canada and Quebec flags
The Canadian CRO's hire will be focused on helping clients in the earlier stages of devlepoment (Wikimedia Commons)

Biopharma and CRO veteran Beatrice Setnik, Ph.D., has become the new chief scientific officer at Canadian clinical research firm Altasciences.

Setnik, also a Pfizer alum, joins the company from Syneos Health (created by the merger of inVentiv Health and INC Research) where she spent five years, most recently as its VP of scientific and medical affairs.

Altasciences says that as CSO she will go about “supporting our internal and external clients with her expertise in all areas relating to early drug development.”

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

“We are extremely fortunate to add a candidate of such caliber and talent to our team. We look forward to Dr. Setnik’s contributions which will reinforce Altasciences’ extensive offerings in early phase preclinical and clinical research,” said Chris Perkin, CEO at Altasciences.

Last year, the midsized CRO penned a new deal that saw it snap up the preclinical testing business of SNBL USA.

The buyout added “comprehensive preclinical safety testing services” to Altasciences’ current clinical and bioanalytical offerings, according to its PR.

Algorithme Pharma, Vince & Associates Clinical Research and Algorithme Pharma USA operate under the Altasciences umbrella. Combined, they boast more than 600 beds for phase I/II studies.

Altasciences, which was acquired by Audax Group in June 2017, bought Vince & Associates in 2013. That deal was followed by the launch of Algorithme Pharma USA the next year.

Suggested Articles

IQVIA is still steering around COVID-19 roadblocks with its R&D business still posting a loss, but other segments are recovering.

After snapping up contract research organization Covance for $6.5 billion five years ago, LabCorp is now looking to change the makeup of its drug dev

Siteless Californian trial company Science 37 has penned a new deal with Signant Health for digital studies focused on CNS work.